89bio to participate in the leerink partners global healthcare conference

San francisco, march 03, 2025 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will participate in a fireside chat at the leerink partners global healthcare conference on monday, march 10, 2025 at 4:20 pm est and participate in one-on-one investor meetings. the webcast of the fireside chat will be accessible in the investor section of 89bio's website.
ETNB Ratings Summary
ETNB Quant Ranking